renal disease in diabetes
DESCRIPTION
RENAL DISEASE IN DIABETES. Diabetic Symposium 24th May 2006. Dr Nick Fluck Consultant Nephrologist Aberdeen Royal Infirmary. Diabetic Nephropathy. The Natural History of Diabetic Nephropathy Epidemiology Chronic Kidney Disease Preventing Progression of Diabetic Nephropathy - PowerPoint PPT PresentationTRANSCRIPT
RENAL DISEASE IN DIABETES
Dr Nick Fluck Consultant NephrologistAberdeen Royal Infirmary
Diabetic Symposium 24th May 2006
The Natural History of Diabetic Nephropathy
Epidemiology
Chronic Kidney Disease
Preventing Progression of Diabetic Nephropathy
Management Issues
The Role of the Nephrologist
Diabetic Nephropathy
The Natural History of Diabetic Nephropathy
Epidemiology
Chronic Kidney Disease
Preventing Progression of Diabetic Nephropathy
Management Issues
The Role of the Nephrologist
Diabetic Nephropathy
Natural history of diabetic nephropathy
Development of proteinuria and decline in GFR
1. Silent clinical phase1. Silent clinical phase
HyperfiltrationHyperfiltration
Increased GFRIncreased GFR
2. Microalbuminuria 2. Microalbuminuria
[20 - 200ug/d][20 - 200ug/d]
3. Clinical nephropathy3. Clinical nephropathy
[proteinuria > 0.5g/d][proteinuria > 0.5g/d]
4. Endstage renal failure4. Endstage renal failure
1
2
3
4
Diabetic Nephropathy
Rate of transition between stages of disease
Diabetic Nephropathy
Rate of progression to kidney failure
Diabetic NephropathyDiabetic Nephropathy
Long term risk in Type 1 and Type 2 PatientsLong term risk in Type 1 and Type 2 Patients
• 4% with Type 1 DM will develop nephropathy within 10 years
• 25% with Type 1 DM will develop nephropathy within 25 years
• 10% with Type 2 DM will have nephropathy by 5 years
• 30% with Type 2 DM will have nephropathy by 20 years
• 30% of those with diabetic nephropathy will progress to ESRF
• Substantial associated increase in mortality
Incidence of DiabetesIncidence of Diabetes
Worldwide DataWorldwide Data
Africa Americas EasternMediterranean
Europe SoutheastAsia
WesternPacific
Estim
ated
pre
vale
nce
(milli
ons)
0
10
20
30
40
50
60
70
80Year 1995 2000 2025
Diabetic Nephropathy
The commonest single cause of ESRF
Diagnosis E&W < 65
Scot <65
E&W > 65
Aetiology Uncertain 16 13 23
15 6
Scot >65
M:F (UK)
31 1.6
7 2.2
Diabetes 20 21 10 12 1.4
Glomerulonephritis 13
Polycystic Kidney 9 10 3
Pyelonephritis 9 11 7
2 12
2 1.1
6 1.3
14 2.7
Hypertension 4 5 4 7 2.2
Renal Vascular disease 3
9 1.5Other 12 14 12
Diabetologist 1993; 36: 1099-1104.
Year
5000
4000
3000
2000
1000
0
Num
ber o
f new
Pat
ient
s
1970 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990
Incidence of ESRD due to DiabetesIncidence of ESRD due to Diabetes
European DataEuropean Data
Diabetic NephropathyDiabetic NephropathySummary ISummary I
•Diabetic nephropathy develops over many years
•Type I and Type II patients are equally at risk
•Increasing proteinuria is usually associated with declining GFR
•Diabetic nephropathy is the single commonest cause of ESRF leading
to the need for dialysis or transplantation
The Natural History of Diabetic Nephropathy
Epidemiology
Chronic Kidney Disease
Preventing Progression of Diabetic Nephropathy
Management Issues
The Role of the Nephrologist
Diabetic Nephropathy
Chronic Kidney DiseaseChronic Kidney Disease
Measurement of Kidney FunctionMeasurement of Kidney Function
Glomerular Filtration Rate ( GFR )
Other MethodsCalculation based on creatinine, age, wt and sex
24hr urine collections
Radioisotope clearance
Chronic Kidney DiseaseChronic Kidney Disease
Classification based on kidney functionClassification based on kidney function
Glomerular Filtration Rate ( GFR )
NKF K/DOQI Classification SystemStage Description GFR
1 Kidney Damage / Normal or high GFR >902 Kidney Damage / Mild reduction in GFR 60-893 Moderately Impaired 30-594 Severely Impaired 15-295 Advanced or on Dialysis < 15
Chronic Kidney DiseaseChronic Kidney Disease
Classification based on kidney functionClassification based on kidney function
NKF K/DOQI Classification System
Association with complications
Stage GFR BP Hb Diet Bone Physical
1 >902 60-90 67% 14.5 1.10 2 to 10 5%3 30-59 80% 14 1.00 2 to 12 8%4 15-29 88% 12 0.94 4 to 32 22%5 <15 94% 10.5 0.88 8 to 70 30%
Chronic Kidney DiseaseChronic Kidney Disease
Classification based on kidney functionClassification based on kidney function
NKF K/DOQI Classification System
Cardiovascular Complications
Stage LVH CCF/IHD CVD Death Framingham
12 27% 58% 17.90%
3 31% 58% 17.90%
4 45% 58%5 40% RR 15
Chronic Kidney DiseaseChronic Kidney Disease
Progressive diseaseProgressive disease
y = -0.01x + 527.30
R2 = 0.93
0
10
20
30
40
50
60
70
28-O
ct-9
5
11-M
ar-9
7
24-J
ul-9
8
6-D
ec-9
9
19-A
pr-0
1
1-S
ep-0
2
14-J
an-0
4
28-M
ay-0
5
Creat (umol/l)
Date ("Month/Year")
MDRD GFR
88 07-Feb-97 64.3222042104 05-Mar-99 51.96999778107 21-Sep-99 50.03711582123 21-Dec-99 42.50734859139 27-Nov-01 36.29647766147 20-Dec-02 33.73266766168 17-Jan-03 28.89762474187 11-Mar-03 25.50720327154 31-Jul-03 31.81564309151 02-Dec-03 32.46058369189 16-Mar-04 24.99779198179 28-Sep-04 26.50860229181 25-Jan-05 26.10759453
MDRD Plot
Date when GFR is 15 Date when GFR is 10 Date when GFR is 5May-06 Apr-07 Apr-08
Rate of GFR Loss per year 5.18Rate of GFR Loss per month 0.43
Diabetic NephropathyDiabetic NephropathySummary IISummary II
•Progression of Diabetic Nephropathy can be mapped to the K/DOQI
Chronic Kidney Disease classification system.
•Cardiovascular disease is the main complication of CKD
•Anaemia, Renal Bone Disease and Constitutional symptoms are
relatively late features of CKD
•Those with progressive CKD require particular attention
The Natural History of Diabetic Nephropathy
Epidemiology
Chronic Kidney Disease
Preventing Progression of Diabetic Nephropathy
Management Issues
The Role of the Nephrologist
Diabetic Nephropathy
Diabetic Nephropathy
Preventing Progression
Preventing development of Microalbuminuria
Preventing progression to overt Proteinuria
Slowing Rate of Loss of GFR
Diabetic Nephropathy
Preventing Progression
Education
Glycaemic control
Hypertension control
ACEI and ARB
Strict glycaemic control
Prevents microalbuminuria in type I diabetics
0
5
10
15
20
25
30
0 1 2 3 4 5 6 7 8 9 10
Years
conventionalcontrol
intensivecontrol
DCCT, 1993,NEJM329: 977
% patients
Strict glycaemic control
Prevents microalbuminuria in type 2 diabetics
Review of evidenceStrippoli G et al. BMJ 2004; 329: 828-39
43 trials in total looking at effects of ACE inhibitors or ARBs on 43 trials in total looking at effects of ACE inhibitors or ARBs on mortality and renal outcomes in diabetic nephropathymortality and renal outcomes in diabetic nephropathy
36 trials: ACE inhibitors compared with placebo36 trials: ACE inhibitors compared with placebo
4 trials: ARBs compared with placebo4 trials: ARBs compared with placebo (IRMA, IDNT, RENAAL)(IRMA, IDNT, RENAAL)
3 trials: ACE inhibitors compared with ARBs3 trials: ACE inhibitors compared with ARBs
Conclusions from ARB/ACE Trials
BP reduction slows progression of diseaseBP reduction slows progression of disease
ACE I can prevent development of microalbuminuriaACE I can prevent development of microalbuminuria
ACE I / ARB can reduce progression rate to overt proteinuria and ACE I / ARB can reduce progression rate to overt proteinuria and can reverse microalbuminuriacan reverse microalbuminuria
ARB can reduce rate of GFR lossARB can reduce rate of GFR loss
Dual Blockade may offer enhance protectionDual Blockade may offer enhance protection
Both agents reduce overall CVS mortalityBoth agents reduce overall CVS mortality
Diabetic NephropathyDiabetic NephropathySummary IIISummary III
•Rate of disease progression can be slowed
•Glycaemic control
•BP control
•ACE I or ARB
•ACE I and ARB
•Education
The Natural History of Diabetic Nephropathy
Epidemiology
Chronic Kidney Disease
Preventing Progression of Diabetic Nephropathy
Management Issues
The Role of the Nephrologist
Diabetic Nephropathy
Diabetic NephropathyDiabetic Nephropathy
Management IssuesManagement Issues
Stage 1 + 2 GFR > 60 mls/min/1.73m2
Microalbuminuria
Stage 3 GFR 30 to 60
Proteinuria
Stage 4 GFR 15 to 30
Proteinuria
Some will be Nephrotic
Stage 5 GFR < 15
Diabetic NephropathyDiabetic Nephropathy
Management Issues Stage 1 + 2 CKDManagement Issues Stage 1 + 2 CKD
Education
Detection
Measures to slow progression
Cardiovascular risk reduction
Diabetic NephropathyDiabetic Nephropathy
Management Issues Stage 3 CKDManagement Issues Stage 3 CKD
Education
Detection
Measures to slow progression
Cardiovascular risk reduction
Identification of those with progressive GFR loss
Early Renal Bone Disease
Diabetic NephropathyDiabetic Nephropathy
Management Issues Stage 4 CKDManagement Issues Stage 4 CKD
Education
Detection
Measures to slow progression
Cardiovascular risk reduction
Identification of those with progressive GFR loss
Renal Bone Disease
Anaemia
Volume Control
Acidosis
RRT Preparation
Diabetic NephropathyDiabetic Nephropathy
Management Issues Stage 5 CKDManagement Issues Stage 5 CKD
Education
Detection
Cardiovascular risk reduction
Renal Bone Disease
Anaemia
Volume Control
Acidosis
RRT Preparation
Commence RRT Dialysis
Transplant
Conservative
The Natural History of Diabetic Nephropathy
Epidemiology
Chronic Kidney Disease
Preventing Progression of Diabetic Nephropathy
Management Issues
The Role of the Nephrologist
Diabetic Nephropathy
Is this really diabetic nephropathy
Advanced Renal Disease
Progressive Renal Disease
The Role of the Nephrologist
Is it really diabetic nephropathy ?
Non-diabetic glomerular disease present in 8 - 28 % of diabetic patients proceeding to renal biopsy
All forms of glomerular disease have been identified in patients with diabetes
Features to look for• Early onset• Lack of retinopathy• Haematuria• Early nephrotic syndrome
Treatment of Advanced Renal Disease
Stage 4 + 5
•Education
•Anaemia
•Renal Bone Disease
•Preparation for Renal Replacement Therapy
The Role of the Nephrologist
Stage 3 with progressive renal disease
Two observational studies from Bristol and Glasgow
Significant reduction in rate of GFR loss in first year after referral - halved in the Glasgow study.
No one reason• Intense follow up• Better BP control• More ACEI usage• Removal of nephrotoxic drugs
Diabetic NephropathyDiabetic NephropathySummary IVSummary IV
•This is a common condition placing a major burden on patients, our society
and healthcare resources
•It is treatable.
•Blood pressure control should be very tight. ACE I or ARB are the drugs of
choice
•Glycaemic control should be optimised
•Patients with advanced disease, deteriorating function or an atypical
presentation should be seen by a nephrologist